Cybin Inc. Common Shares (CYBN)
5.8600
+0.00 (0.00%)
NYSE · Last Trade: Sep 28th, 4:16 AM EDT
Detailed Quote
| Previous Close | 5.860 |
|---|---|
| Open | 5.920 |
| Bid | 5.750 |
| Ask | 5.920 |
| Day's Range | 5.720 - 5.960 |
| 52 Week Range | 4.810 - 13.88 |
| Volume | 573,969 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 730,575 |
Chart
About Cybin Inc. Common Shares (CYBN)
Cybin Inc is a biotechnology company focused on developing innovative psychedelic-based therapeutic solutions to address various mental health disorders. The company is engaged in research and clinical development of psychedelic compounds, aiming to enhance mental health treatment options through advanced drug formulations and delivery methods. By leveraging the potential of psychedelics, Cybin strives to provide patients with new avenues for healing and improved quality of life, while also working to advance the understanding and acceptance of psychedelic therapies in mainstream medicine. Read More
News & Press Releases
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 24, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Highlights Clinical and Regulatory Milestones, Prepares for Upcoming Catalysts
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage breakthrough neuropsychiatry company, outlined key advancements across its proprietary drug discovery platforms and upcoming milestones. The Company emphasized its intellectual property portfolio extending through 2041 and its scalable manufacturing partnership with Thermo Fisher Scientific for the CYB003 program. Key near- and mid-term catalysts include topline data from the CYB004 Phase 2 program in generalized anxiety disorder (Q1 2026), topline readouts from the CYB003 Phase 3 APPROACH study in major depressive disorder (Q4 2026), initiation of the Phase 3 EMBRACE study (Q4 2025) with approvals across multiple international sites, and ongoing enrollment in the EXTEND long-term safety study. Earlier Phase 2 data from CYB003 demonstrated 100% response rates and 71% remission rates maintained at 12 months, with CYB003 having FDA Breakthrough Therapy Designation for expedited development.
Via Investor Brand Network · September 24, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today highlights significant clinical and regulatory milestones and upcoming value-driving catalysts as the Company advances multiple programs towards potential commercialization.
By Cybin Inc. · Via Business Wire · September 23, 2025
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 14, 2025
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or “the Company”) (NYSE American: CYBN) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · September 11, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives to Present at TD Cowen Neuropsychiatry & Epilepsy Summit
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options, announced that Chief Medical Officer Amir Inamdar and Chief Business Officer George Tziras will participate in a fireside chat at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on Sept. 17, 2025, at 9:20 a.m. ET.
Via Investor Brand Network · September 11, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Amir Inamdar, Cybin’s Chief Medical Officer, and George Tziras, Cybin’s Chief Business Officer, will participate in a fireside chat at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on Wednesday, September 17, 2025, at 9:20 a.m. ET.
By Cybin Inc. · Via Business Wire · September 11, 2025
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 10, 2025
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes Enrollment in Phase 2 CYB004 Study for Generalized Anxiety Disorder
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options, announced it has completed enrollment in its Phase 2 study of CYB004, a proprietary deuterated dimethyltryptamine (DMT) program for the treatment of Generalized Anxiety Disorder (GAD). Topline data are expected in the first quarter of 2026. Interim CEO Eric So said the milestone supports Cybin’s mission to deliver effective therapies for the roughly 6.8 million people in the U.S. living with GAD, half of whom do not respond to existing treatments. He noted CYB004’s potential to provide convenient intramuscular dosing and emphasized the program’s strong patent protection.
Via Investor Brand Network · September 8, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced completion of enrollment in its Phase 2 study evaluating CYB004, a proprietary deuterated dimethyltryptamine (“DMT”) program, for the treatment of Generalized Anxiety Disorder (“GAD”) and reaffirms top line data guidance expected in the first quarter of 2026.
By Cybin Inc. · Via Business Wire · September 8, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at H.C. Wainwright Global Investment Conference
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options, announced that Chief Business Officer George Tziras will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 8, 2025, at 11:00 a.m. ET.
Via Investor Brand Network · September 4, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that George Tziras, Cybin’s Chief Business Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:00 a.m. ET.
By Cybin Inc. · Via Business Wire · September 4, 2025
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Participate in Cantor Global Healthcare Conference
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options for mental healthcare, announced that Chief Medical Officer Amir Inamdar will take part in a fireside chat at the Cantor Global Healthcare Conference, scheduled for Sept. 3–5, 2025. The session will be webcast live on Friday, Sept. 5, at 10:20 a.m. ET, with an archived replay available on Cybin’s investor relations website.
Via Investor Brand Network · September 3, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Amir Inamdar, Cybin’s Chief Medical Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference, taking place September 3-5, 2025.
By Cybin Inc. · Via Business Wire · September 3, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Appoints Co-Founder Eric So as Interim CEO
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) announced that, effective Sept. 2, 2025, Doug Drysdale stepped down as Chief Executive Officer and was succeeded on an interim basis by Co-Founder and President Eric So. The Board of Directors has formed a committee to conduct a search for a new CEO to lead the Company through commercialization, while So will focus on advancing Cybin’s clinical pipeline, including CYB003 and CYB004, and ensuring continuity during the transition.
Via Investor Brand Network · September 2, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe Canada:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, announced that, effective September 2, 2025, Doug Drysdale will step down as the Company’s Chief Executive Officer. The Company’s Co-Founder and President, Eric So, has been appointed as Interim Chief Executive Officer by the Board of Directors.
By Cybin Inc. · Via Business Wire · September 2, 2025
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Australian Approval to Begin EMBRACE Phase 3 Study of CYB003
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company focused on next-generation treatment options, announced approval in Australia to conduct the EMBRACE study, the second pivotal trial in PARADIGM, its Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. Approval was granted through the Clinical Trial Notification scheme, with clearance from multiple Ethics Committees of the Australian Therapeutics Goods Administration and Research Governance Offices, allowing initiation of the study.
Via Investor Brand Network · August 26, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has received approval in Australia to conduct the EMBRACE® study. EMBRACE is the second pivotal study in PARADIGM™, the Company’s Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. The Company has received approval through the Clinical Trial Notification scheme, obtained clearance from multiple Ethics Committees of the Australian Therapeutics Goods Administration, and the study site Research Governance Offices, thus allowing the commencement of the EMBRACE study.
By Cybin Inc. · Via Business Wire · August 26, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Annual Meeting Voting Results
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation mental healthcare treatments, announced the results of its annual meeting of shareholders held Aug. 18, 2025. A total of 90 shareholders were represented in person or by proxy, holding 11,264,212 common shares, which accounted for 48.92% of the Company’s issued and outstanding common shares as of the record date.
Via Investor Brand Network · August 19, 2025
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company’s annual meeting of shareholders held on August 18, 2025 (the “Meeting”). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:
By Cybin Inc. · Via Business Wire · August 18, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Q1 2025 Results, Advances Phase 3 Depression Program and Nears Completion of Phase 2 Anxiety Study
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation mental health treatments, reported unaudited Q1 2025 results and key program updates. The company gained European Clinical Trial Application and UK MHRA approval to begin EMBRACE, expanding its multinational Phase 3 PARADIGM program of CYB003 for adjunctive treatment of major depressive disorder to approximately 550 participants. The Phase 3 studies target patients with moderate to severe MDD unresponsive to existing antidepressants. Cybin also said its Phase 2 study of CYB004 for generalized anxiety disorder is expected to complete enrollment this month. Management said recent funding positions the company to advance both programs through multiple upcoming inflection points.
Via Investor Brand Network · August 14, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2025, and is pleased to provide an update on key business milestones.
By Cybin Inc. · Via Business Wire · August 13, 2025
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives EU Approval to Launch EMBRACE Phase 3 MDD Study
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, announced European approval to initiate its EMBRACE(TM) Phase 3 study in Ireland, Poland, and Greece. EMBRACE is part of the Company’s PARADIGM(R) program evaluating CYB003, a proprietary deuterated psilocin analog granted Breakthrough Therapy Designation by the FDA for Major Depressive Disorder. The study will enroll 330 participants with inadequately controlled MDD symptoms across multiple international sites, assessing two CYB003 dose levels against placebo.
Via Investor Brand Network · August 7, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that its Clinical Trial Application (“CTA”) has been approved by the Irish Medicines Board, acting as the reference Member state, to initiate the EMBRACE™ study in Ireland, Poland, and Greece. EMBRACE is the second pivotal study in PARADIGM®, the Company’s Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. The Company also recently announced approval from the Medical and Healthcare products Regulatory Agency (“MHRA”) to commence EMBRACE in the United Kingdom.
By Cybin Inc. · Via Business Wire · August 7, 2025
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Present at Canaccord Genuity Growth Conference
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation mental health treatments, announced that CEO Doug Drysdale will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston. The live webcast will take place at 2:30 p.m. ET, with an archived version available on Cybin’s investor relations site.
Via Investor Brand Network · August 6, 2025